74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Johnson and Johnson
Open
Sector Healthcare
162.43 1.88
Overview
Share price change
24h
Min
159.22
Max
162.59
Income | 3.4B |
|---|---|
Sales | 20M 23B |
P/E Sector Avg | 27.269 73.394 |
EPS | 2.04 |
Dividend yield | 3.14 |
Profit margin | 15.235 |
Employees | 138,100 |
EBITDA | 652M 5.9B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +4.9 upside |
Dividend yield Sector Avg | 3.14% 3.09% |
|---|---|
Next Earnings | 15 Apr 2025 |
Next Dividend date | 4 Mar 2025 |
Next Ex Dividend date | 19 May 2025 |
Market Cap | 13B 380B |
|---|---|
Previous open | 160.55 |
Previous close | 162.43 |
News Sentiment
By Acuity
33%
67%
110 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Johnson and Johnson Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Johnson and Johnson Forecast
Price Target
By TipRanks
4.9% upside
12 Months Forecast
Average 167.5 USD 4.9%
High 185 USD
Low 152 USD
Based on 14 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.
Sentiment
By Acuity
110 / 393 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Johnson and Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
